Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23518055 | 1.00 | PIK3CD (0.65) | PIK3CDTP53MDM2GRIN1GRIN2B | |
| SCHEMBL12058789 | 0.83 | PIK3CD (0.69) | PIK3CDTP53MDM2GRIN1GRIN2B | |
| SCHEMBL15354726 | 0.81 | PIK3CD (0.72) | PIK3CDTP53MDM2GRIN1GRIN2B | |
| SCHEMBL15354755 | 0.81 | PIK3CD (0.72) | PIK3CDTP53MDM2GRIN1GRIN2B | |
| SCHEMBL8282177 | 0.79 | PIK3CD (1.00) | PIK3CDTP53MDM2GRIN1GRIN2B | |
| SCHEMBL18881211 | 0.79 | PIK3CD (0.68) | PIK3CDTP53MDM2GRIN1GRIN2B | |
| SCHEMBL12040109 | 0.78 | PIK3CD (0.61) | PIK3CDTP53MDM2GRIN1GRIN2B | |
| SCHEMBL21009380 | 0.78 | PIK3CD (0.61) | PIK3CDTP53MDM2GRIN1GRIN2B | |
| SCHEMBL21009688 | 0.78 | PIK3CD (0.61) | PIK3CDTP53MDM2GRIN1GRIN2B | |
| SCHEMBL12040052 | 0.78 | PIK3CD (0.61) | PIK3CDTP53MDM2GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2022-06-02 | — | — | US | disclosed |
| US-20210179560-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | PIK3CD 493/4885TP53 2/4885MDM2 1/4885 |
| US-20210179560-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | PIK3CD 493/4885TP53 2/4885MDM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.